NextPharma
NextPharma Technologies Holding, a leading contract manufacturer in Europe for the pharmaceutical, biotechnology and healthcare industries, has announced the sale of Bioserv Corporation, its US affiliate based in San Diego, to KESA Partners, Inc.
The sale supports NextPharma’s growth strategy of focusing on its core specialty and conventional product and technology operating platform in Europe. NextPharma continues to expand its sales and marketing presence in North America and to develop long-term partnerships with North American customers.
Franck Latrille, Chief Executive Officer, NextPharma, commented: “The divestment of Bioserv represents a successful step in the implementation of NextPharma’s strategy, enabling us to focus our growth strategy on NextPharma’s core strengths and areas of expertise. I would like to thank Bioserv’s employees for their efforts and contributions over the past years and I wish each of them, as well as Bioserv’s customers and new owners, a successful future.”
Al Hansen, Managing Partner, KESA Partners, added: “This is an exciting time for Bioserv. For almost 20 years, Bioserv has been known for its quality, flexibility and responsiveness to customers’ unique requirements. Bioserv is well positioned to benefit from the increased outsourcing in the pharmaceutical industry. Bioserv has a strong foundation to build upon. By enhancing our capabilities and emphasising excellence in quality and execution, Bioserv will become a leader in the contract manufacturing space.”
NextPharma Technologies Holding Ltd, +44 1483 479 120, www.nextpharma.com.